These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 37936597)
1. Toxic Epidermal Necrolysis and Stevens - Johnson Syndrome Following Sintilimab Administration in a Non-Small Cell Lung Cancer Patient: A Case Report. Jiang Z; Chen X; Sun Z; Shen X; Huang Y; Liu J J Inflamm Res; 2023; 16():5061-5067. PubMed ID: 37936597 [TBL] [Abstract][Full Text] [Related]
2. Toxic epidermal necrolysis induced by sintilimab in a patient with advanced non-small cell lung cancer and comorbid pulmonary tuberculosis: A case report. Li G; Gong S; Wang N; Yao X Front Immunol; 2022; 13():989966. PubMed ID: 36090976 [TBL] [Abstract][Full Text] [Related]
3. A case of toxic epidermal necrolysis associated with lenvatinib and sintilimab therapy for intrahepatic cholangiocarcinoma. Gong Y; Mao J; Liu M; Gao J J Int Med Res; 2023 May; 51(5):3000605231173556. PubMed ID: 37211771 [TBL] [Abstract][Full Text] [Related]
4. Toxic epidermal necrolysis associated with chemoimmunotherapy for lymphoma: case report and literature review. Yang W; Xu X; Xia D; Wang H; Jiang J; Yang G Immunotherapy; 2022 Apr; 14(5):275-282. PubMed ID: 35128931 [TBL] [Abstract][Full Text] [Related]
5. Case Report: Toxic epidermal necrolysis associated with sintilimab in a patient with relapsed thymic carcinoma. Yang H; Ma Q; Sun Y; Zhang K; Xing Y; Li H Front Oncol; 2022; 12():1065137. PubMed ID: 36620577 [TBL] [Abstract][Full Text] [Related]
6. Toxic Epidermal Necrolysis Induced by Sintilimab: A Case Report. Lye YL; Shan B; Jia CH; Liu J; Hou J; Du WL; Feng R; Liang P Ann Dermatol; 2023 May; 35(Suppl 1):S100-S102. PubMed ID: 37853877 [TBL] [Abstract][Full Text] [Related]
7. Lichenoid dermatitis following PD-1 inhibitor-induced toxic epidermal necrolysis: a case report and literature review. Zhang L; Wang L; Cheng Q; Lei X; Wu J; Chen N Immunotherapy; 2023 Oct; 15(15):1249-1256. PubMed ID: 37585673 [TBL] [Abstract][Full Text] [Related]
8. Treatment of PD-1 Inhibitor-Associated Toxic Epidermal Necrolysis: A Case Report and Brief Review. Zhao Y; Cao Y; Wang X; Qian T Onco Targets Ther; 2022; 15():345-351. PubMed ID: 35422628 [TBL] [Abstract][Full Text] [Related]
9. Adalimumab for Sintilimab-Induced Toxic Epidermal Necrolysis in a Patient with Metastatic Gastric Malignancy: A Case Report and Literature Review. Zhang L; Wu Z Clin Cosmet Investig Dermatol; 2023; 16():457-461. PubMed ID: 36846442 [TBL] [Abstract][Full Text] [Related]
10. Toxic epidermal necrolysis associated with pembrolizumab. Cai ZR; Lecours J; Adam JP; Marcil I; Blais N; Dallaire M; Belisle A; Mathieu A J Oncol Pharm Pract; 2020 Jul; 26(5):1259-1265. PubMed ID: 31810421 [TBL] [Abstract][Full Text] [Related]
11. Sintilimab-induced erythema multiforme drug eruption in the treatment of sigmoid colon cancer: A case report and literature review. Zhang M; Wu R; Jia M; Sun S; Zhang L; Tang T Medicine (Baltimore); 2023 Oct; 102(41):e35659. PubMed ID: 37832081 [TBL] [Abstract][Full Text] [Related]
12. Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience. Çekiç Ş; Canıtez Y; Sapan N Turk Pediatri Ars; 2016 Sep; 51(3):152-158. PubMed ID: 27738400 [TBL] [Abstract][Full Text] [Related]
13. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors. La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941 [TBL] [Abstract][Full Text] [Related]
14. Case Report: sintilimab-induced Stevens-Johnson Syndrome in a patient with advanced lung adenocarcinoma. Li X; Li G; Chen D; Su L; Wang RP; Zhou Y Front Oncol; 2023; 13():912168. PubMed ID: 37781182 [TBL] [Abstract][Full Text] [Related]
15. Cutaneous Stevens Johnson - Toxic Epidermal Necrolysis Immunotherapy related Toxicities in Lung Cancer Patients. Alexandris D; Alevizopoulos N; Gakiopoulou H; Stavrinou N; Vourlakou C J Oncol Pharm Pract; 2022 Jul; 28(5):1276-1282. PubMed ID: 35038934 [TBL] [Abstract][Full Text] [Related]
16. Pembrolizumab-induced Stevens-Johnson syndrome/Toxic Epidermal Necrolysis in a Vietnamese patient with nonsmall-cell lung cancer. Pham YTH; Vu MT; Nguyen AQ; Trinh PN; Tran MH; Chu HC; Nguyen NTM; Vu CHV; Nguyen DV Asia Pac Allergy; 2024 Jun; 14(2):84-89. PubMed ID: 38827262 [TBL] [Abstract][Full Text] [Related]
17. Case report: A rare case of sintilimab-induced gastric stenosis and literature review. Song K; Dong H; Jiang S; Xu X; Zhang C; Chen Q; Wang Q Front Oncol; 2023; 13():1091459. PubMed ID: 36761970 [TBL] [Abstract][Full Text] [Related]
18. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: An Analysis of Triggers and Implications for Improving Prevention. Miliszewski MA; Kirchhof MG; Sikora S; Papp A; Dutz JP Am J Med; 2016 Nov; 129(11):1221-1225. PubMed ID: 27086495 [TBL] [Abstract][Full Text] [Related]
19. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Association with Commonly Prescribed Drugs in Outpatient Care Other than Anti-Epileptic Drugs and Antibiotics: A Population-Based Case-Control Study. Frey N; Bodmer M; Bircher A; Jick SS; Meier CR; Spoendlin J Drug Saf; 2019 Jan; 42(1):55-66. PubMed ID: 30112729 [TBL] [Abstract][Full Text] [Related]
20. Drug-related Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Review. Arora R; Pande RK; Panwar S; Gupta V Indian J Crit Care Med; 2021 May; 25(5):575-579. PubMed ID: 34177178 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]